RO 7795081
Alternative Names: CT-996; RG-6652; RO-7795081Latest Information Update: 28 Jun 2026
At a glance
- Originator Carmot Therapeutics
- Developer Carmot Therapeutics; Roche
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for phase-I development in Obesity in Australia (PO, Capsule)
- 28 Jun 2026 No recent reports of development identified for phase-I development in Obesity in Mexico (PO, Capsule)
- 28 Jun 2026 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Australia (PO, Capsule)